The Effects of NOx and Conjugated Linoleic Acid on Asthmatics (NICLA)
Primary Purpose
Asthma
Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Conjugated Linolenic Acid
Sodium Nitrite
Sodium Nitrate
Sponsored by

About this trial
This is an interventional treatment trial for Asthma focused on measuring Asthma, Obesity, conjugated linolenic acid, nitrate, nitrite, nutritional supplements
Eligibility Criteria
Inclusion Criteria:
- Adequate completion of informed consent process with written documentation
- Male and female patients, ≥ 18 - 65 yrs old
- Diagnosis of asthma: based on previous physician diagnosis and either baseline pre-bronchodilator FEV1 50% or greater predicted with a 12% or greater bronchodilator response to 4 puffs of albuterol or PC20 methacholine (16 mg) if no BD response.If the subject is not currently on an ICS/ ICS LABA, PC20 should be < 8 mg, if no BD response. Spirometry results within the prior 24 months located in the subject's medical records can be used to determine eligibility, if available.
- All racial/ethnic backgrounds with a diagnosis of asthma for ≥6 months
- Smoking history ≤10 pack years and no smoking in the last year
- BMI ≥ 30
- If subject is on ICS or ICS/LABA therapy- 30 days on a stable dose (up to 1,000 mcg daily fluticasone equivalent)
- Asthma diagnosed at age 9 or later
Exclusion Criteria:
- Respiratory tract infection within the last 4 weeks
- Oral or systemic CS burst within the last 4 weeks
- Asthma-related hospitalization within the last 2 months
- Asthma-related ER visit within the previous 4 weeks
- Significant or uncontrolled concomitant medical illness including (but not limited to) heart disease, cancer, diabetes
- Chronic renal failure (creatinine > 2.0) at screening (Associated with higher ADMA levels)
- Current statins use (statins lower ADMA levels), patients may stop and re-enroll after 2 weeks of stopping statins
- Positive pregnancy test
- Intolerance or allergy to the intervention drugs
- Current or recent (within 30 days) in an investigational treatment study.
- Unable or unlikely to complete study assessments or the study intervention (i.e. bronchoscopy) poses undue risk to patient in the opinion of the Investigator.
- Any kind of oral nitrates such as nitroglycerin or already taking supplements
- History of ICU admission/intubation due to asthma in the past year;
- More than three systemic corticosteroid requiring asthma exacerbations in the past year
- Systemic steroid dependent asthma (no daily oral steroids- short term therapy for asthma exacerbation is permitted)
- Use of mouthwash containing chlorhexidine (lowers NO) within 1 week prior to screening and throughout the study
- Untreated sleep apnea
- Hgb A1C ≥7
- Daily use of PPI's (Proton Pump Inhibitor) or H2 Blockers for GERD (it is permitted to take on an occasional basis- no more than 1x per week. If participants wash out of these meds for 1 week, they can enroll)
- Use of biologics for asthma/allergies unless there is a 4 month washout prior to enrollment (the washout for biologics is done for clinical reasons and not specifically for inclusion for the study).
- Drug and/or alcohol abuse for ≥1 year
- Breastfeeding
- Any other condition and/or situation that causes the investigator to deem a subject unsuitable for the study (e.g. due to expected study medication non-compliance, inability to medically tolerate the study procedures, or a subject's unwillingness to comply with study-related procedures.
Sites / Locations
- The University of Pittsburgh Asthma Institute at UPMC
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Conjugated Linolenic Acid + NOx
Arm Description
This is a single arm study Conjugated Linolenic Acid (CLA)- daily oral dose 3 g/day Sodium Nitrate- Capsules for daily oral administration at the dose of 1 g (2 x 500 mg) Sodium Nitrite- Capsules for daily oral administration at the dose of 20 mg (2 x 10 mg)
Outcomes
Primary Outcome Measures
Change in Exhaled NO Before and After Treatment
Determine how CLA and NOx affect airway NO bioavailability (exhaled NO)
Secondary Outcome Measures
Biomarkers of Inflammation-bronchial Hyperresponsiveness Using PC20
To determine whether, compared to baseline, treatment with NOx + CLA can reduce bronchial hyperresponsiveness. PC20 was measured by methacholine challenge (mg/mL) in three participants pre and post supplementation with Nitrate/Nitrite and cLA
Biomarkers of Inflammation- Concentration of Free CLA in Plasma
To determine whether, compared to baseline, treatment with NOx + CLA can quantify the concentrations of free CLA in plasma
Number of Participants With an Increase in IL-6 and IL-1b Expression
To determine whether, compared to baseline, treatment with NOx + CLA will increase a participant's IL-6 and IL-1b expression.
Biomarkers of Inflammation-airway XO Activity
To determine whether, compared to baseline, treatment with NOx + CLA can effect airway XO activity determined in endobronchial biopsies
Biomarkers of Inflammation-15NO2-cLA
To determine whether, compared to baseline, treatment with NOx + CLA can effect measurement of 15NO2-cLA in urine.
Biomarkers of Inflammation-anion Superoxide
To determine whether, compared to baseline, treatment with NOx + CLA can decrease production of anion superoxide in fresh airway epithelial cells
Number of Participants With a Decrease of Inflammation Using Mitochondrial ROS Production
To determine whether, compared to baseline, treatment with NOx + CLA can decrease inflammation using mitochondrial ROS production in fresh and cultured airway epithelial cells.
Biomarkers of Inflammation- Concentration of NO2-CLA in Plasma
To determine whether, compared to baseline, treatment with NOx + CLA can quantify the concentrations of NO2-cLA in plasma
Biomarkers of Inflammation- Concentration of NO2-CLA in Urine
To determine whether, compared to baseline, treatment with NOx + CLA can quantify the concentrations of NO2-cLA in urine
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02433977
Brief Title
The Effects of NOx and Conjugated Linoleic Acid on Asthmatics
Acronym
NICLA
Official Title
A Proof of Concept Study to Determine the Effects of NOX and Conjugated Linoleic Acid on Asthmatics
Study Type
Interventional
2. Study Status
Record Verification Date
April 2021
Overall Recruitment Status
Completed
Study Start Date
September 2015 (Actual)
Primary Completion Date
November 2019 (Actual)
Study Completion Date
November 2019 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Gladwin, Mark, MD
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This study will examine the hypothesis that in obese asthmatics; treatment with NOx + CLA is well tolerated, safe and will increase eNO while reducing airway oxidative stress. Allied with this, the investigators will define whether supplementing with this bioactive mediator modifies the airway microbiome, and reduces airway inflammation.
Detailed Description
Obesity is an asthma comorbidity associated with increased severity, poor control, reduced steroid responsiveness and greater exacerbation and healthcare utilization rates. These associations are not explained by having a greater degree of Th-2 inflammation. Rather, the obese asthma phenotype defined in several cluster studies, has paradoxically reduced levels of Th-2 biomarkers, including sputum eosinophils and exhaled nitric oxide (NO). The investigators previous research has shown that the inverse relation between increased body mass index (BMI) and reduced exhaled NO, may be explained by a metabolic imbalance characterized by lower L-arginine and greater asymmetric di-methyl arginine (ADMA) levels. Having a low L-arginine/ADMA ratio has been shown to inhibit and uncouple all isoforms of nitric oxidase synthase (NOS), thereby reducing NO bioavailability and promoting oxidative stress through enhanced superoxide production. In obese asthmatics, this imbalance not only correlates with exhaled NO, but also with lower FEV1% and poorer asthma-related quality of life. Yet the effect of obesity in asthma is unlikely to be solely dependent on a single mechanism. Other factors, such as increased Th1 and Th-17-mediated inflammation have been shown to occur in human and animal models. Given all of these potential avenues, it is imperative that an intervention is sufficiently pleiotropic that can, in addition to restoring airway NO levels, also reduce other obesity-related non-Th2 mechanism of inflammation. The investigators hypothesize that treatment with conjugated linolenic acid (CLA) + nitrate and nitrite (together known as NOx), will restore NO airway bioavailability, reduce oxidative stress and improve airway inflammation in obese asthmatics. To test this hypothesis, the investigators propose a phase II pilot study in which obese asthmatics with metabolic syndrome, will be treated orally with CLA+NOx for 8 weeks, in an open label study design to assess pre to post-intervention changes in airway and systemic biomarkers, and to determine the effects on lung function and bronchial hyperresponsiveness. Participants will undergo a pre and post intervention bronchoscopy. The results obtained from this project will be greatly informative to our understanding of the obese - asthma pathophysiology and for the development of clinical trials to determine the potential benefit of this intervention in improving health outcomes.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Asthma
Keywords
Asthma, Obesity, conjugated linolenic acid, nitrate, nitrite, nutritional supplements
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
6 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Conjugated Linolenic Acid + NOx
Arm Type
Experimental
Arm Description
This is a single arm study
Conjugated Linolenic Acid (CLA)- daily oral dose 3 g/day
Sodium Nitrate- Capsules for daily oral administration at the dose of 1 g (2 x 500 mg)
Sodium Nitrite- Capsules for daily oral administration at the dose of 20 mg (2 x 10 mg)
Intervention Type
Dietary Supplement
Intervention Name(s)
Conjugated Linolenic Acid
Other Intervention Name(s)
conjugated linolenic acid (CLA)
Intervention Description
CLA is a polyunsaturated fatty acid Subjects will receive capsules for daily oral administration at the dose of 3 g/day
Intervention Type
Drug
Intervention Name(s)
Sodium Nitrite
Intervention Description
Subjects will receive capsules for daily oral administration at the dose of 20 mg (2 x 10 mg)
Intervention Type
Drug
Intervention Name(s)
Sodium Nitrate
Intervention Description
Subjects will receive capsules for daily oral administration at the dose of 1g (2 x 500 mg)
Primary Outcome Measure Information:
Title
Change in Exhaled NO Before and After Treatment
Description
Determine how CLA and NOx affect airway NO bioavailability (exhaled NO)
Time Frame
Before treatment at baseline and after treatment at 8 weeks
Secondary Outcome Measure Information:
Title
Biomarkers of Inflammation-bronchial Hyperresponsiveness Using PC20
Description
To determine whether, compared to baseline, treatment with NOx + CLA can reduce bronchial hyperresponsiveness. PC20 was measured by methacholine challenge (mg/mL) in three participants pre and post supplementation with Nitrate/Nitrite and cLA
Time Frame
Before treatment at baseline and after treatment at 8 weeks
Title
Biomarkers of Inflammation- Concentration of Free CLA in Plasma
Description
To determine whether, compared to baseline, treatment with NOx + CLA can quantify the concentrations of free CLA in plasma
Time Frame
Before treatment at baseline and after treatment at 8 weeks
Title
Number of Participants With an Increase in IL-6 and IL-1b Expression
Description
To determine whether, compared to baseline, treatment with NOx + CLA will increase a participant's IL-6 and IL-1b expression.
Time Frame
Before treatment at baseline and after treatment at 8 weeks
Title
Biomarkers of Inflammation-airway XO Activity
Description
To determine whether, compared to baseline, treatment with NOx + CLA can effect airway XO activity determined in endobronchial biopsies
Time Frame
Before treatment at baseline and after treatment at 8 weeks
Title
Biomarkers of Inflammation-15NO2-cLA
Description
To determine whether, compared to baseline, treatment with NOx + CLA can effect measurement of 15NO2-cLA in urine.
Time Frame
Before treatment at baseline and after treatment at 8 weeks
Title
Biomarkers of Inflammation-anion Superoxide
Description
To determine whether, compared to baseline, treatment with NOx + CLA can decrease production of anion superoxide in fresh airway epithelial cells
Time Frame
Before treatment at baseline and after treatment at 8 weeks
Title
Number of Participants With a Decrease of Inflammation Using Mitochondrial ROS Production
Description
To determine whether, compared to baseline, treatment with NOx + CLA can decrease inflammation using mitochondrial ROS production in fresh and cultured airway epithelial cells.
Time Frame
Before treatment at baseline and after treatment at 8 weeks
Title
Biomarkers of Inflammation- Concentration of NO2-CLA in Plasma
Description
To determine whether, compared to baseline, treatment with NOx + CLA can quantify the concentrations of NO2-cLA in plasma
Time Frame
Before treatment at baseline and after treatment at 8 weeks
Title
Biomarkers of Inflammation- Concentration of NO2-CLA in Urine
Description
To determine whether, compared to baseline, treatment with NOx + CLA can quantify the concentrations of NO2-cLA in urine
Time Frame
Before treatment at baseline and after treatment at 8 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Adequate completion of informed consent process with written documentation
Male and female patients, ≥ 18 - 65 yrs old
Diagnosis of asthma: based on previous physician diagnosis and either baseline pre-bronchodilator FEV1 50% or greater predicted with a 12% or greater bronchodilator response to 4 puffs of albuterol or PC20 methacholine (16 mg) if no BD response.If the subject is not currently on an ICS/ ICS LABA, PC20 should be < 8 mg, if no BD response. Spirometry results within the prior 24 months located in the subject's medical records can be used to determine eligibility, if available.
All racial/ethnic backgrounds with a diagnosis of asthma for ≥6 months
Smoking history ≤10 pack years and no smoking in the last year
BMI ≥ 30
If subject is on ICS or ICS/LABA therapy- 30 days on a stable dose (up to 1,000 mcg daily fluticasone equivalent)
Asthma diagnosed at age 9 or later
Exclusion Criteria:
Respiratory tract infection within the last 4 weeks
Oral or systemic CS burst within the last 4 weeks
Asthma-related hospitalization within the last 2 months
Asthma-related ER visit within the previous 4 weeks
Significant or uncontrolled concomitant medical illness including (but not limited to) heart disease, cancer, diabetes
Chronic renal failure (creatinine > 2.0) at screening (Associated with higher ADMA levels)
Current statins use (statins lower ADMA levels), patients may stop and re-enroll after 2 weeks of stopping statins
Positive pregnancy test
Intolerance or allergy to the intervention drugs
Current or recent (within 30 days) in an investigational treatment study.
Unable or unlikely to complete study assessments or the study intervention (i.e. bronchoscopy) poses undue risk to patient in the opinion of the Investigator.
Any kind of oral nitrates such as nitroglycerin or already taking supplements
History of ICU admission/intubation due to asthma in the past year;
More than three systemic corticosteroid requiring asthma exacerbations in the past year
Systemic steroid dependent asthma (no daily oral steroids- short term therapy for asthma exacerbation is permitted)
Use of mouthwash containing chlorhexidine (lowers NO) within 1 week prior to screening and throughout the study
Untreated sleep apnea
Hgb A1C ≥7
Daily use of PPI's (Proton Pump Inhibitor) or H2 Blockers for GERD (it is permitted to take on an occasional basis- no more than 1x per week. If participants wash out of these meds for 1 week, they can enroll)
Use of biologics for asthma/allergies unless there is a 4 month washout prior to enrollment (the washout for biologics is done for clinical reasons and not specifically for inclusion for the study).
Drug and/or alcohol abuse for ≥1 year
Breastfeeding
Any other condition and/or situation that causes the investigator to deem a subject unsuitable for the study (e.g. due to expected study medication non-compliance, inability to medically tolerate the study procedures, or a subject's unwillingness to comply with study-related procedures.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Sally E Wenzel, MD
Organizational Affiliation
The University of Pittsburgh Asthma Institute at UPMC
Official's Role
Principal Investigator
Facility Information:
Facility Name
The University of Pittsburgh Asthma Institute at UPMC
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15213
Country
United States
12. IPD Sharing Statement
Learn more about this trial
The Effects of NOx and Conjugated Linoleic Acid on Asthmatics
We'll reach out to this number within 24 hrs